Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Drug Repurposing in Oncology: Current Evidence and Future Direction

Author(s): Zhenzhan Zhang, Jianguang Ji* and Hao Liu*

Volume 28 , Issue 11 , 2021

Published on: 20 August, 2020

Page: [2175 - 2194] Pages: 20

DOI: 10.2174/0929867327999200820124111

Price: $65

Abstract

Background: Drug repurposing, the application of known drugs and compounds with a primary non-oncology purpose, might be an attractive strategy to offer more effective treatment options to cancer patients at a low cost and reduced time.

Methods: This review described a total of 10 kinds of non-oncological drugs from more than 100 mechanical studies as well as evidence from population-based studies. The future direction of repurposed drug screening is discussed by using patient-derived tumor organoids.

Results: Many old drugs showed previously unknown effects or off-target effects and can be intelligently applied for cancer chemoprevention and therapy. The identification of repurposed drugs needs to combine evidence from mechanical studies and population-based studies. Due to the heterogeneity of cancer, patient-derived tumor organoids can be used to screen the non-oncological drugs in vitro.

Conclusion: These identified old drugs could be repurposed in oncology and might be added as adjuvants and finally benefit patients with cancers.

Keywords: Drug repurposing, anti-cancer, population cohort, drug screening, organoid, future direction of cancer.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy